Demo S.A. Pharmaceutical Industry

What Demo S.A. Pharmaceutical Industry does

Demo S.A. Pharmaceutical Industry (operating as DEMO Pharmaceuticals) is a privately held Greek pharmaceutical manufacturer founded in 1965 and headquartered in Krionéri, Attica, Greece. The company develops, produces, and markets injectable pharmaceutical products and is the largest pharmaceutical manufacturer in Greece by units produced and the largest producer of injectable medicines in Southeast Europe. Its manufacturing base centers on a 66,000 sq.m. injectable drugs plant in Kryoneri—the largest of its kind in the region—supplemented by four production plants, a Thessaloniki R&D Centre for chemical APIs inaugurated in 2022, an Agios Stefanos Biotechnology R&D Centre for biosimilars and monoclonal antibodies, and a Tripoli Industrial Complex under construction for APIs and finished pharmaceutical products. Product offerings span more than 3,300 globally approved branded items across hospital injectables (antibiotics, cephalosporins, carbapenems, penicillins, antivirals, sterile solutions, anesthetics, oncology, intensive care, parenteral nutrition), prescription medications, medical devices (including hemodialysis solutions and equipment), and medical nutrition.

DEMO generates revenue by selling these products through direct B2B relationships with public and private hospitals, ministries of health, and global procurement agencies, supplemented by a network of dealers and partner suppliers across 96 countries (branded products present in 86). The company is an official supplier to major international organizations including the United Nations, UNICEF, WHO, Médecins Sans Frontiès, and the International Committee of the Red Cross, and operates a wholly-owned German subsidiary (DEMO Pharma GmbH, established 2015) and a China branch office (2013) for international distribution. Approximately 80% of annual production is exported. The company does not publicly disclose specific product pricing, with commercial terms negotiated through tenders and institutional contracts. A €350+ million 2021–2027 investment plan, partially funded through the EU Recovery and Resilience Facility Greece 2.0, supports vertical integration from raw materials through finished products and expansion into biologics and complex generics.

Name

Demo S.A. Pharmaceutical Industry

Legal name

DEMO S.A. Pharmaceutical Industry

Website

https://demo.gr

Company type

Private

Founded year

1965

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Demo S.A. Pharmaceutical Industry is a Greek, privately held manufacturer of injectable pharmaceuticals, supplying hospitals, ministries of health, and international organizations across 96 countries with 3,300+ approved products.

Ownership category

akta.pro rank

Product category

Injectable Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Injectable pharmaceuticals
• Pharmaceutical manufacturing
• Hospital medications
• Sterile drug production
• Active pharmaceutical ingredients

Headquarters

HQ city

Krionéri

HQ country

Greece

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: DEMO generates revenue through the manufacture and sale of pharmaceutical products including injectable medicines, prescription medications, medical devices, and nutritional supplements. The company serves hospitals, private markets, and international customers across 96 countries. With over 3,300 branded products approved globally, the company maintains leading position in the Greek hospital market.

Go-to-market motion2 records

Distribution channels6 records

Marketing channels7 records

Core offering

DEMO S.A. is a vertically integrated pharmaceutical manufacturer that develops, produces, and markets a diversified portfolio of over 3,300 globally approved products. Its core offering is injectable pharmaceutical products for the hospital market, including large and small volume infusions, antibiotics (cephalosporins, carbapenems, penicillins), antivirals, oncology treatments, sterile solutions, anesthetics, parenteral nutrition, and nephrology/hemodialysis solutions. The company also supplies prescription medications, medical devices, and nutritional supplements to public hospitals, private healthcare providers, ministries of health, and international aid organizations across 96 countries.

Product overview

DEMO S.A. Pharmaceutical Industry is a vertically integrated pharmaceutical manufacturer offering a diversified portfolio of over 3,300 globally approved products. The core offering consists of injectable pharmaceutical products for the hospital market (large volume infusions, antibiotics, antivirals, oncology, intensive care, parenteral nutrition, nephrology), prescription medications across multiple therapeutic areas, medical devices (artificial kidney products, eye care, wound care), and nutritional supplements. The company operates manufacturing facilities including the 66,000 sq.m. Kryoneri plant (largest injectable drugs facility in Southeast Europe) and the Tripoli Industrial Complex. R&D activities span chemical API development at the Thessaloniki centre (2022) and biological/biosimilar development including monoclonal antibodies at the Agios Stefanos Biotech Research Centre. The company also maintains subsidiaries in Germany and China for international market presence.

Differentiator

Problem solved

Functional benefit

Products and services

• Hospital Market Pharmaceuticals Comprehensive portfolio of injectable pharmaceutical products for hospital use, including large and small volume infusions, antibiotics (non-β-lactams, cephalosporins, carbapenems, penicillins), antivirals, sterile solutions, anesthetics/analgesics, intensive care solutions, parenteral nutrition, gastroprotective agents, hematology, pulmonology, and CNS medications. Sold primarily to public hospitals and healthcare institutions.
• Prescription Medications Prescription medications covering pathology, cardiology, hematology/oncology, gastroenterology, urology, and rheumatology therapeutic areas for the private market.
• Medical Nutrition Products Nutritional supplements for liver function support, urinary system support, productive cough relief, lipid profile improvement, blood glucose maintenance, and pediatric vitamins in gummy/jelly form.
• Medical Devices Medical devices including artificial kidney products, contact lens solutions, eye care solutions, cold and flu spray, healing spray for wounds, sterile irrigation solutions for local use, twist-off sterile water, and 0.9% Sodium Chloride irrigation solutions for nose, eyes, and ears.
• Oncology Pharmaceuticals Oncology treatments including antineoplastic agents, erythropoietin, iron chelating agents, and monoclonal antibodies for cancer therapy, including development of three monoclonal antibodies for malignant neoplasms by 2030.
• Nephrology Solutions Complete range of hemodialysis solutions, hemodiafiltration solutions, and distributed medical devices for hemodialysis including machines, dialysis filters, vascular access needles, catheters, hemostatic dressings, and blood lines.

Quantifiable outcome

• 30% of European penicillin needs to be covered by DEMO's Tripoli facility upon completion
• +6 more outcomes

Named customers7 records

Segments6 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Five partnerships are on record, tiered core and supporting.

• Panhellenic Union of Pharmaceutical Industries (P.E.F.)coreOthersDEMO is a member of the Panhellenic Union of Pharmaceutical Industries (P.E.F.), participating in industry advocacy and policy development for the Greek pharmaceutical sector.
• Hellenic Association of Pharmaceutical Companies (S.F.E.E.)coreOthersDEMO is a member of the Hellenic Association of Pharmaceutical Companies (S.F.E.E.) and follows the strict framework of rules dictated by the Code of Ethics of SFEE in matters of compliance.
• Workable Software LimitedsupportingTechnology or IntegrationDEMO uses Workable, an online application provided by Workable Software Limited, to assist with recruitment processes. Workable processes personal information as a data processor on DEMO's behalf.
• Greek Universities and Academic InstitutionssupportingStrategic or Co-development PartnerDEMO maintains partnerships with universities and academic institutions through student associations, career days, webinars, mentoring programs, and other initiatives to provide young professionals with access to employment opportunities and combat brain drain.
• International Aid Organizations (UNICEF, UN, WHO, MSF, ICRC)coreOthersDEMO is an official supplier to major international aid organizations including UNICEF, United Nations, World Health Organization, Médecins Sans Frontières, and International Committee of the Red Cross, supporting their vital missions in providing essential medical services globally.

Scale indicators16 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Sun Pharmaceutical Industries: One of the largest specialty generic injectable manufacturers in India with global distribution across 100+ countries, including a meaningful hospital and oncology injectable franchise. Comparable to DEMO in product mix (sterile injectables, antibiotics, specialty generics), breadth of approved dossiers, and export-heavy revenue model.
• Fresenius Kabi: Fresenius Kabi is the global leader in clinical nutrition, IV drugs, and medical devices for hospital use, with a vertically integrated injectable portfolio in Southeast Europe and beyond. Comparable to DEMO as a direct competitor in hospital IVs, parenteral nutrition, sterile injectable manufacturing, and critical-care products across dozens of countries.
• Gland Pharma: India-headquartered injectable specialist serving global hospital markets with small-volume parenterals, including oncology injectables. Closely comparable to DEMO as a vertically integrated injectable CDMO/manufacturer with global regulatory approvals (US FDA, EU GMP) supplying hospital generics on a tender-driven, multinational basis.
• Hikma Pharmaceuticals: Hikma is one of the largest generic injectable pharmaceutical manufacturers globally, with a hospital-focused injectable portfolio and branded generics across MENA, Europe, and the US. It is the closest direct peer to DEMO in terms of product mix (sterile injectables, hospital channel, branded generics), geographic breadth, and reliance on multi-jurisdictional regulatory approvals.
• Aurobindo Pharma: Indian generic and specialty injectables manufacturer with a leading global position in cephalosporins, sterile injectables, and oncology. Comparable to DEMO in injectable antibiotics (cephalosporins/carbapenems), oncology manufacturing capacity, and global filing-led export model.

Broad incumbents

• Stada Arzneimittel: European generic and specialty pharma group with hospital injectables, biosimilars, and consumer health. Comparable to DEMO in European-focused generic injectables, hospital-channel emphasis, and growing biosimilar/biologic portfolio, though at broader product breadth and via M&A-driven geographic reach.
• Sandoz (Novartis): Sandoz is the global #1 generic injectables player (post-spin) with a broad hospital injectables portfolio and biosimilars pipeline. Comparable to DEMO as a peer in hospital sterile injectables and biosimilars, but at meaningfully larger scale, broader geographic reach, and as a multi-decade biosimilar incumbent.
• Teva Pharmaceutical Industries: Teva is one of the world's largest generic injectable manufacturers, with hospital-channel specialty injectables and a broad specialty pharma franchise. Comparable to DEMO in hospital injectable generics and biosimilar ambitions but at materially larger scale and with global brand recognition.

Regional players

• Krka, d.d., Novo Mesto: Slovenian generic and specialty pharmaceutical manufacturer with hospital injectable presence across Central and Eastern Europe. Direct regional peer to DEMO in CEE hospital-channel injectables, prescription generics, and EU cGMP-certified manufacturing for export-led CEE/CEEMEA business.
• Zentiva Group: Czech-headquartered European generics manufacturer with strong Central/Eastern European hospital injectables and prescription generics business. Comparable to DEMO as a pan-European generic injectables peer with similar customer base (tender-driven ministries of health, hospitals) and overlapping geographies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCNeOWdYXC-vwovKS4V_qoQw
• Facebookfacebook.com/demopharmaceuticals
• LinkedInlinkedin.com/company/demo-pharmaceuticals-s-a-

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Demo S.A. Pharmaceutical Industry